DHA AND EPA IN THE REDUCTION OF OXIDATIVE STRESS
The present invention generally relates to the prevention or treatment of disorders related to oxidative stress. For example, the present invention provides a composition for use in the prevention or treatment of oxidative stress related disorders under post-operative conditions. One embodiment of the present invention is a composition comprising DHA and EPA as active ingredients for use in the treatment or prevention of oxidative stress and/or related disorders.
1 . A method for the treatment, prevention or alleviation of oxidative stress and/or related disorders induced by ischemia-reperfusion comprising administering a composition comprising DHA and EPA as active ingredients to a patient in need of same.
2 . Method in accordance with claim wherein the composition comprises EPA and DHA in a weight ratio of about 2:1 to 1:1.
3 . Method in accordance with claim 1 , wherein DHA and EPA are provided from a lipid source comprising marine oils.
4 . Method in accordance with claim al, wherein the composition comprises a lipid source selected from the group consisting of cocoa butter, soybean oil, fish oil and sunflower oil.
5 . Method in accordance with claim 4 , wherein the lipid source about 5-10 weight-% cocoa butter, about 45-55 weight-% soybean oil, about 15-25 weight-% fish oil and about 20-25 weight-% sunflower oil.
6 . Method in accordance with claim 3 , wherein the lipid source comprises about 18-22 weight-% saturated fatty acids, about 20-25 weight-% monounsaturated fatty acids and about 50-55 weight-% polyunsaturated fatty acids.
7 . Method in accordance with claim 1 , wherein the oxidative stress related disorder is linked to the presence of free radicals in a body.
8 . Method in accordance with claim 1 for the treatment or prevention of oxidative damage to an organ selected from the group consisting of intestine, liver, lung, heart, kidney, and/or skin.
9 . Method in accordance with claim 1 , wherein the oxidative stress related disorder is selected from the group consisting of an inflammatory response to oxidative stress, retinal degeneration, mitohormesis, atherosclerosis, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Friedreich' s ataxia, tardive dyskynesia, brain injuries, skin photoaging, reperfusion injury or stroke, myocardial infarction, hypertension, heart failure, epilepsy, hyperhomocysteinemia, physiological senescence, sepsis, stress following organ transplantation and combinations thereof.
10 . Method in accordance with claim 1 to limit intestinal damages following ischemia-reperfusion (IR).
11 . Method in accordance with claim 1 , wherein EPA and DHA are provided in a daily dose of at least 400 mg.
12 . Method in accordance with claim 1 , wherein the composition is to be administered daily over a period of at least 3 days.
13 . Method in accordance with claim 1 , wherein the patient is a human or pet.
14 . Method in accordance with claim 1 , wherein the composition to be administered is a treatment selected from the group consisting of topically, orally, enterally and parenterally.
15 . Method in accordance with claim 1 , wherein the composition is selected from the group consisting of a food product, a pet food product, a nutraceutical, a drink, a food supplement, a powdered nutritional formula to be reconstituted in milk or water, and a medicament.